Cancer patient experience: percentage of patients who reported whether they experienced excellent communication from healthcare professionals throughout their cancer care on the Cancer Quality Performance Indicator (QPI) Communication Measurement Tool. | National Quality Measures Clearinghouse

Cancer patient experience: percentage of patients who reported whether they experienced excellent communication from healthcare professionals throughout their cancer care on the Cancer Quality Performance Indicator (QPI) Communication Measurement Tool. | National Quality Measures Clearinghouse

Measure Summaries

NHS Scotland

• Cancer patient experience: percentage of patients who reported whether they experienced excellent communication from healthcare professionals throughout their cancer care on the Cancer Quality Performance Indicator (QPI) Communication Measurement Tool.
• Cancer patient experience: percentage of patients who reported whether they experienced excellent information provision from healthcare professionals throughout their cancer care on the Cancer Quality Performance Indicator (QPI) Information Measurement Tool.
• Cancer patient experience: percentage of patients who reported whether they have been enabled by healthcare professionals to share decisions about their care and treatment on the Cancer Quality Performance Indicator (QPI) Shared Decision Making Measurement Tool.
• Cervical cancer: proportion of patients with cervical cancer undergoing primary radical radiotherapy who have PET/CT imaging prior to starting treatment.
• Cervical cancer: proportion of patients with cervical cancer undergoing radical radiotherapy (external beam or brachytherapy) whose overall treatment time, from start to the end of treatment, is not more than 56 days.
• Cervical cancer: proportion of patients with cervical cancer undergoing radical radiotherapy who receive concurrent chemotherapy.
• Cervical cancer: proportion of patients with cervical cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
• Cervical cancer: proportion of patients with cervical cancer who have an MRI of the pelvis performed prior to definitive treatment.
• Cervical cancer: proportion of patients with cervical cancer who undergo surgery where surgical margins are clear of tumour.
• Cervical cancer: proportion of patients with FIGO stage IB1 cervical cancer who undergo radical hysterectomy.
• Testicular cancer: proportion of patients with metastatic testicular cancer undergoing systemic anti-cancer therapy (SACT) within 3 weeks of a multidisciplinary team (MDT) decision to treat with SACT.
• Testicular cancer: proportion of patients with metastatic testicular cancer who have serum tumour markers (STMs) checked 2 weeks before starting chemotherapy.
• Testicular cancer: proportion of patients with stage I seminoma receiving adjuvant single dose carboplatin area under the curve of 7 mg/ml/min (AUC7), based on ethylene diamine tetra-acetic acid (EDTA) clearance, within 8 weeks of orchidectomy.
• Testicular cancer: proportion of patients with stage I testicular non-seminomatous (or mixed) germ cell tumour (NSGCT) who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.
• Testicular cancer: proportion of patients with testicular cancer undergoing orchidectomy where the histological pathology report contains tumour type and size, vascular invasion and rete stromal invasion (based upon the current Royal College of Pathologists dataset).
• Testicular cancer: proportion of patients with testicular cancer undergoing orchidectomy who undergo pre-operative assessment of the testicle which, at a minimum, includes: (i) serum tumour markers (STMs) and (ii) testicular ultrasound.
• Testicular cancer: proportion of patients with testicular cancer undergoing primary orchidectomy within 2 weeks of ultrasonographic diagnosis.
• Testicular cancer: proportion of patients with testicular cancer who are discussed at a multidisciplinary team (MDT) meeting to agree on a definitive management plan post orchidectomy.
• Testicular cancer: proportion of patients with testicular cancer who die within 30 days of treatment for testicular cancer.
• Testicular cancer: proportion of patients with testicular cancer who undergo CT scanning of the chest, abdomen and pelvis within 3 weeks of orchidectomy.
• Upper gastrointestinal (GI) cancer: proportion of patients undergoing surgical resection for oesophageal or gastric cancer who are discharged within 21 days of surgical procedure.
• Upper gastrointestinal (GI) cancer: proportion of patients with gastric cancer who undergo surgical resection where greater than or equal to 15 lymph nodes are resected and pathologically examined.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who are referred to a dietitian within 4 weeks of diagnosis.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who die within 30 or 90 days of surgical resection for oesophageal or gastric cancer.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who have a histological diagnosis made following initial endoscopy and biopsy.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who have tumour node metastases (TNM) stage and treatment intent recorded at a multidisciplinary team (MDT) meeting prior to treatment.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive curative oncological treatment who die within 30 days of treatment.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive neo-adjuvant chemotherapy who then undergo surgical resection.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive palliative oncological treatment who die within 30 days of treatment.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo CT of the abdomen +/- chest +/- pelvis.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo curative treatment.
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo surgical resection in which circumferential and longitudinal surgical margin is clear of tumour (i.e., negative surgical margin).
• Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo surgical resection in which longitudinal surgical margin is clear of tumour (i.e., negative surgical margin).